Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the
leading causes of cancer-related death worldwide. Despite many therapeutic advances in …

Currently, immunotherapy based on PD-1/PD-L1 pathway blockade has improved survival
of non-small cell lung cancer (NSCLC) patients. However, differential responses have been …

Abstract Non-Small-Cell Lung Cancer (NSCLC) is considered one of the most frequently
diagnosed cancers and the leading cause of cancer-related deaths worldwide. Despite the …

Immunotherapies including immune checkpoint blockade (ICB) have become integral to
treatments for immunogenic tumors by reinvigorating host immune functions to attack tumor …

Immunotherapy has revolutionized the treatment paradigm of non-small cell lung cancer and
improved patients' prognosis. Immune checkpoint inhibitors have quickly become standard …

Addressing the urgent need to prevent breast cancer postoperative recurrence and brain
metastasis, Fe-metal organic framework (MOF)-coated hollow mesoporous organosilica …

Highlights•Artesunate inhibited the expression of TAZ and PD-L1 in NSCLC.•Artesunate
suppressed TAZ/PD-L1-induced T-cell growth inhibition.•Artesunate enhanced anti-tumor …

Opinion statement Immunotherapy is revolutionizing tumor treatment by activating the
immune response to tumors. Among them, immunotherapy represented by immune …

Simple Summary Lung cancer is the leading cause of cancer-related death worldwide.
Nonsmall cell lung cancer (NSCLC) accounts for 80–85% of all cases. Immune checkpoint …

Simple Summary Lung cancer is the leading cause of cancer-related deaths.
Immunotherapy activates the patient's immune system to identify and kill cancer cells …